while macro conditions remain variable across our key geographies, we're projecting total sales in the second quarter to grow sequentially to between $num-one billion and $num-two billion resulting in adjusted earnings per share of $num-three to $num-four.
and based on our first quarter earnings, we are raising full year adjusted earnings per share guidance to $num-one to $num-two, up from $num-three to $num-four.
this stronger-than-expected sales performance fell through to the bottom line, resulting in adjusted earnings per share of $num-one, which was num-two% higher than the first quarter of year-five.
for total edwards, we expect sales of $num-one billion to $num-two billion; for tavr, $num-three billion to $num-four billion; for tmtt, approximately $num-five million; for surgical structural heart, $num-six million to $num-seven million; and for critical care, $num-eight million to $num-six million.
we reported $num-one billion in sales this quarter, up num-two% on a constant currency basis from a year ago.
total sales grew num-one% year-over-year on an underlying basis, which was better than the flat growth we expected when we gave guidance for the first quarter back in january.
in surgical structural heart, first quarter year-six global sales was $num-one million, increased num-two% on an underlying basis over the prior year.
in tavr, first quarter global sales were $num-one million, up num-two% on an underlying basis.
in critical care, first quarter sales of $num-one million increased num-two% on an underlying basis, driven by increased sales of technologies for both the operating room and intensive care units.
we continue to expect average diluted shares outstanding for year-six to be between num-one million and num-two million.
in summary, based on the strength we saw at the end of the first quarter, we have confidence that the underlying tavr sales will grow in the num-one% to num-two% range in year-six.
in fact, we recently converted one of our facilities into a mass covid vaccination site to support the community of num-one million people, where our company is headquartered.
also earlier this month, we received approval to begin treating patients at low surgical risk in japan with sapien num-one.
we remain confident in our year-six sales guidance of $num-one million as we advance commercialization, staying focused on physician training, procedural success and patient outcomes.
we continue to believe the current $num-one billion surgical structural heart market will grow in the mid-single digits through num-two.
relative to our january guidance, fx rates positively impacted our first quarter earnings per share by about $num-one.